Nestlé, Roche and Novartis from India — the Swiss blue-chip playbook

Switzerland is a tiny equity market that punches absurdly above its weight. Three companies — Nestlé, Roche and Novartis — together make up the bulk of the SMI, and each is a globally dominant, slow-compounding, defensive franchise of exactly the kind Indian investors say they want more of: low drama, hard currency, decades of dividend growth. The case for owning a slice of Swiss quality is genuinely strong. The case for owning it carelessly is not, because Switzerland pairs that quality with one of the most punishing dividend withholding taxes on earth — a flat 35% at source — and the route you choose to buy these names changes how much of it you ever get back.

This guide is the practical playbook: which names actually matter, how an Indian resident buys them (the SIX listing versus the US ADR), where the 35% bite happens and how much of it is recoverable, and what you owe back home in capital-gains tax and Schedule FA disclosure. The honest framing up front: individual Swiss shares make sense when you have conviction in specific companies and want the franchise and the dividend stream. If you only want "Switzerland in my portfolio," an SMI or SPI ETF is almost always the cleaner tool. This is for the investor who has decided they want the shares themselves.

The names worth knowing

The Swiss large-cap universe is small and top-heavy. A handful of names account for most of what an Indian investor actually buys. Tickers and yields are as of early 2026 — confirm live figures before trading.

Company	SIX ticker	US ADR	Sector	Approx. dividend yield
Nestlé	NESN.SW	NSRGY	Consumer staples	~3.5–4%
Roche	ROG.SW (ROP after conversion)	RHHBY	Pharma / diagnostics	~3%
Novartis	NOVN.SW	NVS	Pharma	~3%
UBS	UBSG.SW	UBS	Banking / wealth mgmt	~2%

Nestlé is the world's largest food and beverage company — Nescafé, KitKat, Purina, a roughly 20% stake in L'Oréal, and one of the longest dividend-growth records in Europe. It is the prototypical defensive compounder, which is exactly why its high dividend yield makes the withholding question matter so much.

Roche is a pharma and diagnostics giant and one of the more confusing share structures in Europe. Historically the liquid, widely held instrument was the non-voting Genussschein. At its 2026 annual general meeting Roche approved converting those Genussscheine into participation certificates (Partizipationsscheine, ticker ROP) — economically similar non-voting paper. For an Indian retail buyer this is mostly a label change, but it means you may see the listing referenced as ROG or ROP depending on the date and data source. Confirm the live ticker your broker routes to.

Novartis is the other Swiss pharma major, now a pure-play innovative-medicines company after spinning off Alcon (eye care) in 2019 and Sandoz (generics) in 2023. If you held Novartis through those spin-offs you would have received shares in the new entities — relevant if you are buying a position that pre-dates them or reading older cost-basis guidance.

UBS is the surviving Swiss banking giant after absorbing Credit Suisse in 2023, now an outsized global wealth manager. It is more cyclical and more volatile than the three defensives above, and it is the one name here where the investment case is about the bank's integration and balance sheet rather than steady compounding.

How to buy them — the two real routes

There are two clean ways for an Indian resident to own these companies, and the choice has direct tax consequences.

Route 1 — the SIX Swiss Exchange listing (CHF)

You buy NESN.SW, ROG.SW / ROP, NOVN.SW or UBSG.SW directly on the SIX Swiss Exchange in Swiss francs. This is the "real" share — the primary listing, the deepest liquidity, the cleanest price. International brokers that route to SIX include Interactive Brokers, Saxo Bank and Swissquote. You will need an account that supports European-exchange trading; the India-fintech wrappers built around US stocks generally do not offer SIX access, so this route usually means a global broker.

The mechanics of buying are unremarkable — it trades like any other stock. The catch is entirely on the dividend side: a Swiss dividend paid to you on the SIX line is hit with the full 35% Swiss withholding tax at source, and you then have to actively reclaim the excess over your treaty rate. We cover that machinery in depth in the Swiss withholding reclaim guide. The headline: the Switzerland–India treaty rate is 10%, so on the SIX line you over-pay by 25 percentage points and reclaim it via the ESTV reclaim form for residents of India (confirm the current form number on the ESTV site).

Route 2 — the US ADR (USD)

Nestlé (NSRGY), Roche (RHHBY) and Novartis (NVS) all trade as American Depositary Receipts in the US. An ADR is a US-listed receipt representing the underlying Swiss shares, held by a depositary bank. For an Indian investor whose entire setup is already built around US-stock brokers — Vested, INDmoney, Interactive Brokers — the ADR is operationally the path of least resistance. You buy it in dollars, in the same account where you hold your US ETFs, with the same LRS remittance flow.

The ADR convenience comes with two wrinkles you must understand:

• The Swiss withholding still applies underneath. An ADR does not magically escape Swiss tax. The dividend is paid in Switzerland, the 35% Swiss withholding is deducted before it reaches the depositary, and what lands in your account is net of Swiss tax. Some depositaries apply relief-at-source down to a treaty-ish rate; many do not, and reclaiming the excess through an ADR is materially messier than reclaiming on a directly held SIX position, because you are one layer removed from the Swiss tax authority. Read your ADR's dividend documentation before assuming you will get the 10% treaty rate cleanly.
• The ADR introduces US-situs exposure. This is the trap most people miss. An ADR is a US-listed security, and US-listed securities are generally US-situs assets for US estate-tax purposes. So owning Nestlé via NSRGY can pull you into the US estate-tax net for non-residents — the $60,000 exemption, up to 40% above it, no India–US estate treaty — even though Nestlé is a Swiss company. Owning Nestlé on the SIX line (NESN.SW) is a Swiss-situs asset and sits outside that US trap. For a large, long-held position this is not a footnote; it can be the deciding factor.

The short version: the SIX line is the cleaner long-term holding (Swiss-situs, full and direct reclaim path, hard-currency pricing), while the ADR is the more convenient short-to-medium-term holding if your whole life is already in a US brokerage and the position is small enough that estate tax is irrelevant.

The dividend tax — where most of your return leaks

These are dividend-heavy names. Nestlé yields roughly 3.5–4%, Roche and Novartis around 3%. For a buy-and-hold investor the dividend is a big part of the total-return story, which means dividend tax friction is a big part of the real return story. Here is the full chain for an Indian resident holding the SIX line.

1. Switzerland withholds 35% at source. On a CHF 100 dividend, CHF 35 is taken before it reaches you. You receive CHF 65.
2. Your treaty entitlement is 10%. Under the current Switzerland–India DTAA, Switzerland is entitled to keep only 10%. The 25-percentage-point excess (CHF 25 here) is reclaimable.
3. You reclaim the excess via the ESTV reclaim form for residents of India (confirm the current form number on the ESTV site). You file the Swiss reclaim form with proof of Indian tax residence and dividend documentation. The reclaim window is three years from the end of the year the dividend fell due — miss it and the 25% is simply gone. The full process is in the Swiss withholding reclaim guide.
4. India taxes the dividend at your slab rate. The gross dividend (the full CHF 100, not the CHF 65 you received) is added to your income and taxed at your slab — up to ~30% plus surcharge and cess for high earners.
5. You claim a foreign tax credit for the 10% Swiss tax. Via Form 67 (being renumbered Form 44 from TY2026-27) you offset the 10% Switzerland is entitled to against your Indian dividend tax, so you are not taxed twice on the same 10%. Our Form 67 FTC calculator handles the arithmetic.

The thing to internalise: without the reclaim, your effective dividend tax is catastrophic. If you let the 35% stand and then pay Indian slab tax (crediting only the treaty 10%, since that is all the DTAA allows), you have suffered 35% in Switzerland but can only credit 10% in India — the other 25% is a pure, permanent loss stacked on top of your Indian tax. On a high-yield name like Nestlé held for decades, that compounds into a serious drag. The reclaim is not optional housekeeping; it is the difference between Swiss dividends being a good deal and a bad one.

This is also why, for a pure dividend-harvesting strategy, Switzerland is a worse hunting ground than it looks. The franchises are superb; the at-source tax is hostile and the reclaim is paperwork-heavy. Many Indian investors rationally hold these names for total return and treat the dividend reclaim as an annual chore rather than the centrepiece.

Capital gains — the one place Switzerland is generous

Here is the good news that partly redeems the dividend pain. Switzerland levies no tax on private-investor capital gains, for residents or non-residents, on listed shares. When you sell your Nestlé or Novartis at a profit, Switzerland takes nothing. There is no Swiss capital-gains tax to reclaim, no Swiss form to file on a sale, nothing. This is one of the defining features of the Swiss market and a genuine structural advantage.

That does not mean the gain is tax-free for you, of course — it is taxed in India:

• Long-term (held more than 24 months): foreign shares are taxed at 12.5% without indexation under the rules effective from FY 2025-26. Note that the Rs 1.25 lakh exemption that applies to Indian listed equity does not apply to foreign shares — that carve-out is specific to securities covered under the Indian STT regime, which Swiss shares are not. Your Swiss gains are taxed under the general long-term capital-gains provision.
• Short-term (held 24 months or less): taxed at your slab rate, like ordinary income.

So the holding-period threshold for foreign shares is 24 months, not the 12 months that applies to Indian listed equity — a distinction Indian investors trip over constantly. Hold your Swiss names for at least two years and the long-term 12.5% rate applies; sell earlier and you are taxed at slab. You can model the all-in cost with the capital-gains calculator (the foreign-share LTCG logic is identical to the US case).

The currency layer matters too. Your gain is computed in rupee terms, so the CHF/INR move between buy and sell is baked into your taxable gain. The Swiss franc has historically been a strong, safe-haven currency, which has generally helped rupee returns over long periods — but it cuts both ways and you are taxed on the rupee number regardless.

Schedule FA and the LRS plumbing

Two compliance points that are non-negotiable for an Indian resident holding Swiss shares.

Schedule FA is mandatory. Every Swiss share or ADR you held at any point during the financial year must be disclosed in Schedule FA of your Indian income-tax return — the entity, the peak value, the closing value, and dividends received. This applies whether or not you sold and whether or not you made money. The penalties for non-disclosure of foreign assets are severe and run independently of any tax actually due, so this is not a corner to cut. Our Schedule FA helper handles the initial/peak/closing-value math the form demands.

LRS governs the outbound money. Buying Swiss shares means remitting funds abroad under the Liberalised Remittance Scheme — the same $250,000-per-financial-year window that governs all your overseas investing, with TCS collected on remittances above the threshold. If you are also buying US stocks, German shares or anything else offshore, it all draws on the same annual LRS limit. The LRS explainer covers the mechanics and the LRS/TCS calculator shows the tax-collected-at-source impact on a given remittance.

How Switzerland compares to its European peers

If you are building European exposure, it is worth seeing where Switzerland sits relative to its neighbours, because the tax friction varies a lot.

Market	Statutory dividend WHT	India treaty rate	Capital gains for non-residents
Switzerland	35%	10% (reclaim the 25% excess)	0%
Germany	26.375%	10% (reclaim the excess)	0% on listed shares
France	12.8% (individuals)	~10%	0% on listed shares

Switzerland has the highest statutory withholding of the three and the most painful reclaim, but the most generous capital-gains treatment (so does Germany on listed shares; France too). The practical takeaway: Switzerland rewards the long-term, low-turnover, capital-appreciation investor far more than the dividend-income investor, precisely because the gains are clean and the dividends are taxed hard at source. If your thesis on Nestlé or Novartis is "own it for fifteen years and let it compound," Switzerland's tax profile actually suits you. If your thesis is "harvest a fat Swiss dividend yield," reconsider — or at least commit to the annual reclaim religiously.

For the broader menu of markets and how each treats Indian investors, the markets hub lays them out side by side.

What to actually do

If you want direct ownership of Swiss blue chips, the decision tree is short:

• For a core, long-term holding you intend to keep for years, buy the SIX line (NESN.SW, NOVN.SW, ROG.SW/ROP, UBSG.SW) through a global broker. It is Swiss-situs (no US estate-tax exposure), gives you the cleanest direct path to reclaim the 35% withholding down to the treaty 10%, and prices in hard-currency CHF.
• For a small, convenient position where you do not want a second broker, the US ADR (NSRGY, RHHBY, NVS) is fine — just understand that Swiss withholding still applies underneath, the reclaim is messier through the ADR layer, and you take on US-situs estate exposure on a foreign company.
• Whichever route, commit to the dividend reclaim and the Form 67 foreign-tax-credit filing every year, hold for more than 24 months to get the 12.5% long-term rate in India, and disclose everything in Schedule FA.

Swiss quality is real and the capital-gains treatment is a genuine gift. The 35% dividend tax is the toll you pay to access it — and the investors who do best in this market are the ones who treat that toll as a managed annual process rather than an afterthought.

---

This is general information, not tax or legal advice. Withholding rates, treaty positions and Indian capital-gains rules change, and the Roche share-structure conversion and Switzerland–India treaty position are both recent developments — verify the current primary sources before acting. Figures reflect rules as understood in early 2026. For a sizeable cross-border portfolio, consult a qualified tax advisor.